Aclaris Therapeutics
On June 17, 2019, Aclaris Therapeutics Inc. issued a press release announcing positive results from a phase 2 clinical trial for men and women with androgenic alopecia. Trial Details From the press release: the trial results included 22 subjects of both men and women who applied a 0.46% solution of ATI-502 to their scalps twice…
Today, on June 6th 2019, Aclaris made its annual presentation at the Jeffries Global Healthcare Conference in New York City. Eyebrow Growth To Start Aclaris CEO Dr. Neal Walker made the presentation on behalf of his company and shared some impressive eyelash growth results. The slide is shared below and depicts the before photos on the…
Today, there have been updates from two companies with therapies in phase 2 clinical trials for AGA. Initially, I posted the Follicum news to the Updates page, then I later found that Aclaris had released news as well. This was compelling enough to create an article for these news items. Follicum Trial Over 50% Enrolled…
According to its latest press release, Aclaris Therapeutics will be launching a phase 2 trial for the use of JAK inhibitors in androgenic alopecia (pattern hair loss) within the next few months. Here’s the line item from the press release about Aclaris’ trial in androgenic alopecia. AGA-201 Topical – a planned Phase 2 open-label clinical trial…
Hello everyone, and welcome to another edition of Weekly Thoughts. It has been a little while since my last check in with you all. You can chalk it up to a busy schedule and the fact that there hasn’t been too much significant news in the hair growth treatment world recently. As always, there are…
Hello everyone, and welcome to another edition of Weekly Thoughts. Things have been really busy in the hair world as of late, new companies are popping up all the time and companies that we have known about are finally making the announcements we want to hear. Lo and behold it’s almost been two months since…
Hello Everyone, Welcome to another edition of Weekly Thoughts. This edition features a presentation update on the JAK inhibitor therapies for hair growth and the announcement of a new startup/treatment for hair growth that is also claimed to restore hair pigment. Wowzas. Let’s take a look. Aclaris Therapeutics Jeffries Presentation Acalaris Therapeutics CEO Dr. Neal…
Well you guys asked for it, right? An established pharmaceutical company has acquired the rights to Angela Christiano’s hair growth research involving JAK inhibitors. Aclaris Therapeutics has entered into an agreement with Vixen to acquire all of the stock of Vixen Pharmaceuticals. For those unaware, Vixen Pharma is the small startup company that Christiano founded…